ICI rechallenge in mRCC

Affiliations

Comment

David Killock. Nat Rev Clin Oncol. 2020 Sep.

. 2020 Sep;17(9):520.

doi: 10.1038/s41571-020-0407-x.

No abstract available

Comment on

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.
Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, Choueiri TK. Ravi P, et al. JAMA Oncol. 2020 Oct 1;6(10):1606-1610. doi: 10.1001/jamaoncol.2020.2169. JAMA Oncol. 2020. PMID: 32469396 Free PMC article.
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC, Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI. Gul A, et al. J Clin Oncol. 2020 Sep 20;38(27):3088-3094. doi: 10.1200/JCO.19.03315. Epub 2020 Jun 3. J Clin Oncol. 2020. PMID: 32491962 Free PMC article.

1. Gul, A. et al. Salvage ipilimumab and nivolumab in patients with metastatic renal cell carcinoma after prior immune checkpoint inhibitors. J. Clin. Oncol. https://doi.org/10.1200/JCO.19.03315 (2020) - DOI - PubMed
1. Ravi, P. et al. Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.2169 (2020) - DOI - PubMed